Lumakras | Indications/Uses

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Side Effects Drug Interactions Caution For Usage Storage Patient Counseling Information MIMS Class ATC Classification Thai FDA Category Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Indications/Uses

KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): LUMAKRAS as a single agent is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Pharmacology: Pharmacodynamics: Clinical Data under Actions]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC): LUMAKRAS, in combination with panitumumab, is indicated for the treatment of adult patients with KRAS G12C‑mutated metastatic colorectal cancer (mCRC) who have received prior fluoropyrimidine‑, oxaliplatin‑ and irinotecan‑based chemotherapy [see Posology under Dosage & Administration and Pharmacology: Pharmacodynamics: Clinical Data under Actions].

Lumakras Indications/Uses

sotorasib

Manufacturer:

Amgen

Distributor:

Zuellig Pharma